Browse the evidence

In males with type 2 diabetes, higher baseline endogenous total testosterone and lower estradiol levels significantly enhance the reduction of triglycerides achieved through intensive lifestyle intervention.

If you are a man with type 2 diabetes, your baseline testosterone and estradiol levels may dictate how effectively your diet and exercise efforts lower triglycerides. Men with higher testosterone and lower estradiol tend to see bigger improvements in triglycerides from lifestyle changes. This suggests that knowing your hormone profile could help tailor your lifestyle prescription for better lipid outcomes.

In females with type 2 diabetes, higher baseline sex hormone-binding globulin (SHBG) significantly enhances the reduction of LDL cholesterol achieved through intensive lifestyle intervention.

If you are a postmenopausal woman with type 2 diabetes, your baseline SHBG levels may dictate how effectively your diet and exercise efforts lower LDL cholesterol. Women with higher SHBG tend to see bigger improvements in LDL-C from lifestyle changes. This suggests that knowing your hormone profile could help tailor your lifestyle prescription for better lipid outcomes.

Higher baseline total testosterone predicts greater long-term weight loss and waist circumference reduction in both males and females with type 2 diabetes undergoing intensive lifestyle intervention.

If you have type 2 diabetes, your baseline testosterone levels may dictate how effectively your diet and exercise efforts lead to weight loss and waist circumference reduction. Both men and women with higher testosterone tend to see bigger improvements in weight and waist size from lifestyle changes. This suggests that knowing your hormone profile could help tailor your lifestyle prescription for better weight outcomes.

Metabolic bariatric surgery leads to sustained HbA1c reduction, whereas non-surgical management is associated with HbA1c increase in patients with type 2 diabetes.

For patients with severe obesity and type 2 diabetes, metabolic bariatric surgery offers significantly better long-term weight loss and blood sugar control than non-surgical management. While surgery is not for everyone, those who undergo it maintain much greater weight loss (22% vs 8.6%) and better glycemic control over five years. If surgery is not an option, intensive lifestyle modification and pharmacotherapy are critical alternatives to mitigate health risks.

Achieving comprehensive metabolic control (simultaneous HbA1c, LDL-C, and blood pressure targets) significantly reduces the risk of cardiovascular and microvascular complications in diabetic patients.

For diabetic patients, managing blood sugar, blood pressure, and cholesterol together is critical. Missing any one target leaves you at higher risk for heart and kidney damage. Work with your doctor to hit all three goals simultaneously, not just one.

Probiotic and synbiotic supplementation improves glycemic control, lipid profiles, and reduces inflammation in patients with type 2 diabetes and obesity, with strain-specific effects.

Taking specific probiotic or synbiotic supplements daily can modestly improve blood sugar and cholesterol levels in people with diabetes or obesity. Choose strains with clinical evidence (like Lactobacillus acidophilus or Bifidobacterium lactis) and take them consistently for at least 12 weeks.

Visceral fat accumulation is a primary driver of cardiovascular disease in obesity, independent of BMI, through inflammatory and metabolic mechanisms.

Focus on reducing visceral fat through lifestyle changes, not just BMI. Even if your BMI is normal, high waist circumference indicates higher cardiovascular risk.

The protective effect of beneficial dietary components on all-cause mortality is partially mediated by a reduction in systemic inflammation, as measured by the Systemic Inflammation Index (SII).

While reducing inflammation is part of the benefit, it is not the whole story. The dietary components likely work through multiple pathways, including direct gut microbiome effects, not just lowering blood inflammation markers.

The fixed-dose extended-release combination of naltrexone and bupropion (NB-ER) is the most promising pharmacotherapy for facilitating smoking cessation while preventing post-cessation weight gain in individuals with obesity.

If you smoke and have obesity, your fear of gaining weight after quitting is valid and common. Standard cessation drugs often fail to stop this weight gain. Ask your doctor about NB-ER (naltrexone/bupropion extended-release), which targets the brain pathways for both addiction and hunger, offering the best chance to quit smoking without the associated weight gain.

Targeted pharmacotherapy for obesity should focus on the MC4R pathway (e.g., MC4R agonists) for patients with specific genetic defects in upstream genes like POMC, PCSK1, or LEPR.

If you have a known genetic defect affecting your hunger hormones (like POMC or MC4R deficiencies), standard diets may fail. You should ask your doctor about genetic testing. If positive, you may be eligible for targeted medications like setmelanotide (Imcivree) that specifically fix the broken pathway.

Newer GLP-1 and dual-agonist obesity medications produce significant weight loss (15-21%) and metabolic benefits, but discontinuation leads to weight regain.

Use GLP-1 medications as a long-term tool for weight management, not a short-term fix. Be prepared to continue treatment to maintain weight loss, as stopping often leads to regain.

GLP-1 analogs (e.g., Semaglutide, Liraglutide) and dual agonists (Tirzepatide) produce significant weight loss (up to 21%) but are associated with high costs, lifelong administration requirements, and gastrointestinal side effects that may drive patients toward complementary therapies.

GLP-1 drugs (Semaglutide, Tirzepatide) are highly effective for weight loss (15-21%), but they are expensive, require lifelong injections, and cause GI side effects. If you experience side effects or cannot afford long-term use, you are not alone; many patients seek complementary therapies like TCM to manage weight and side effects.

In patients with advanced chronic liver disease (ACLD), achieving >10% body weight loss through therapeutic lifestyle interventions significantly reduces portal hypertension and improves survival, although this magnitude of weight loss is difficult to sustain long-term.

For ACLD patients, aiming for >10% weight loss via diet and exercise can significantly lower portal pressure and improve survival. However, this is hard to maintain; consider medical weight loss aids if lifestyle changes alone fail to sustain the loss.

New generation obesity medications (GLP-1/GIP agonists) achieve mean weight loss of 15–25% over 68–72 weeks, narrowing the efficacy gap between medical and surgical management of obesity.

New GLP-1/GIP medications like semaglutide (2.4mg weekly) and tirzepatide are highly effective, producing 15-25% weight loss over ~1.5 years. This efficacy is now comparable to surgery, making medication a primary, not just secondary, option for obesity treatment.

A Body Shape Index (ABSI) is associated with incident cardiovascular disease, with the highest risk observed in individuals with high ABSI combined with high RCII.

For adults over 45, monitoring your Body Shape Index (ABSI) alongside your cholesterol and inflammation levels (RCII) provides a more accurate assessment of heart disease risk than weight alone. If you have a high ABSI and high RCII, you are in a high-risk subgroup that may benefit from intensified lifestyle interventions.

Among pharmacotherapies, Semaglutide 2.4 mg and Orlistat have the most favorable safety/tolerability profiles, while Liraglutide 3.0 mg has the least tolerability, and Tirzepatide has intermediate tolerability.

When choosing a weight loss medication, be aware that tolerability varies. Semaglutide and Orlistat tend to be better tolerated, while Liraglutide may cause more side effects. Tirzepatide, despite its high efficacy, has intermediate tolerability, meaning you might experience more side effects than with Semaglutide or Orlistat.

Discontinuation of GLP-1 RA or GIP/GLP-1 RA therapy (liraglutide, semaglutide, tirzepatide) leads to rapid and substantial weight regain, effectively reversing the majority of metabolic benefits achieved during treatment.

If you stop taking GLP-1 or GIP/GLP-1 medications (like semaglutide or tirzepatide), you will likely regain most of the weight you lost. The drugs work by altering hormonal signals that regulate hunger and metabolism; when you stop, those signals revert. To maintain weight loss, you likely need to continue the medication long-term or adopt a rigorous, sustainable lifestyle intervention that mimics the drug's effects, though current evidence suggests pharmacological support is often necessary to prevent rebound.

Modulating the gut microbiome and its metabolites through diet, pharmaceuticals (e.g., GLP-1 agonists, SGLT2 inhibitors), or microbiota therapies (e.g., probiotics, FMT) improves glycemic control and ameliorates Type 2 Diabetes complications by influencing pancreatic islet function, hepatic metabolism, and systemic inflammation.

To leverage the gut-diabetes connection, prioritize high-fiber diets to boost beneficial bacteria that produce short-chain fatty acids (SCFAs) and GLP-1. If lifestyle changes are insufficient, discuss GLP-1 receptor agonists (like semaglutide) or dual agonists (like tirzepatide) with your doctor, as these medications directly exploit the gut-pancreas axis to lower blood sugar and promote weight loss. Probiotics (specifically strains like Akkermansia muciniphila) may offer modest additional benefits, but they are not a replacement for core therapies.

Tirzepatide utilization has rapidly displaced other glucose- and weight-lowering medications in the US, with its uptake being steeper and more sustained than previous GLP-1 receptor agonists.

Tirzepatide is currently the fastest-growing and most prescribed glucose- and weight-lowering medication in the US, rapidly replacing older drugs like metformin and other GLP-1s. If you have T2D or obesity, this drug is becoming the standard of care, but access may be difficult due to shortages. Prioritize securing a prescription early if eligible.

Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, achieves up to 24.2% weight loss over 48 weeks.

Retatrutide is an investigational once-weekly injection that targets GLP-1, GIP, and glucagon receptors, achieving up to 24.2% weight loss over 48 weeks in clinical trials. It is not yet fully approved but shows promise for obesity and type 2 diabetes. Potential side effects include gastrointestinal issues and transient heart rate elevations.

GLP-1 receptor agonists and SGLT2 inhibitors are effective pharmacological treatments for T2DM and obesity that target shared pathophysiological mechanisms like inflammation and insulin resistance.

If lifestyle changes are insufficient, ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs help manage blood sugar and weight by targeting hormonal pathways, offering an advantage over older medications that may cause weight gain.

GLP-1 receptor agonists should be discontinued immediately upon confirmation of pregnancy due to the lack of approved safety data, despite current evidence not showing teratogenicity.

Stop taking your GLP-1 medication as soon as you get a positive pregnancy test. Your doctor will likely switch you to insulin or diet management to keep your blood sugar stable, which is the standard of care for diabetes in pregnancy.

Therapeutic reduction of central adiposity via bariatric surgery or incretin-based drugs significantly reduces the risk of heart failure hospitalizations and worsening heart failure events in patients with HFpEF, whereas blood pressure lowering alone yields only modest benefits unrelated to the magnitude of BP reduction.

For HFpEF patients, focusing solely on blood pressure medication is insufficient. Prioritizing significant weight loss through bariatric surgery or incretin-based medications (like semaglutide or tirzepatide) is critical, as these interventions directly reduce the hormonal and mechanical drivers of heart failure, leading to a 50-60% reduction in worsening heart failure events.

Central adiposity (measured by waist-to-height ratio) is a stronger predictor of HFpEF development and severity than systemic hypertension, and adiposity drives hypertension rather than vice versa.

HFpEF patients should prioritize weight loss and visceral fat reduction over aggressive blood pressure targeting alone, as adiposity is the primary driver of the disease process and arterial stiffness.